

A clinical trial to investigate if proton beam therapy with chemotherapy given before surgery for patients with oesophageal cancer that has spread to the surrounding tissues, significantly reduces the severe side effects to the heart and lungs and allows immunotherapy to be started sooner after surgery when compared with standard radiotherapy and chemotherapy before surgery, and whether this delivers value to the NHS and patients

Submission date 27/12/2023	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 15/02/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 06/02/2026	Condition category Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Although the optimal treatment strategy in oesophageal (food pipe) cancer has been the subject of research for several decades, overall outcomes are very poor, with a 5-year survival of 15%. In the UK there are 9100 new cases of oesophago-gastric cancer diagnosed and approximately 7925 deaths every year (Cancer Research UK Oct 2019). Oesophageal cancer is a strategic priority for CRUK and a serious health problem world-wide. Pre-surgery treatment consists of chemotherapy with/without immunotherapy or chemoradiation, but the optimal treatment is unknown. Over 60% of patients experience severe side-effects from their treatment and this impacts their outcomes. Proton beam therapy is a new radiotherapy treatment; there are currently only 2 centres in England with Proton beam therapy machines. Proton beam therapy may help to reduce side-effects and is an important avenue of research. This trial has been funded by CRUK.

This study aims to investigate if Proton beam therapy and chemotherapy given before surgery for oesophageal cancer significantly reduces the risk of severe toxicity and prevents delay of post-operative immunotherapy when compared with standard photon radiotherapy.

Who can participate?

Patients over 16 years old with resectable oesophageal cancer.

What does the study involve?

Patients will be randomised 1:1 into the experimental arm (Proton beam therapy, chemotherapy +/- immunotherapy + surgery) and control arm (photon radiotherapy, chemotherapy +/- immunotherapy + surgery). After surgery patients can be treated with standard of care systemic anti-cancer therapy which would be chemotherapy and/or immunotherapy. Patients suitable for immunotherapy will receive up to 12 months of treatment after surgery as per standard of care. This UK trial will recruit patients from 15 NHS sites; all patients randomised to receive Proton beam therapy will be treated at either UCLH/Christie. Patients will receive treatment for 5-11 weeks before surgery (the duration of chemotherapy depends on the most suitable chemotherapy for their cancer type), and for up to 1 year after surgery. Patients will be followed up at NHS sites for up to 1 year, and then survival data will be collected from NHS data registries for a further 2 years.

What are the possible benefits and risks of participating?

The potential risks and burden will only be applicable to patients randomised to the experimental arm to receive Proton-beam therapy over a period of 3 weeks. Patients on the control arm will be treated as per standard of care. There is a risk of financial burden on patients allocated proton beam therapy who will need to travel to one of the two proton beam centres for their specialised radiotherapy treatment. Patients will be required to organise the travel themselves with the help of their 'key worker' from the relevant Proton beam therapy centre. Patients may also be required to stay away from home for 3 weeks if they live far away from one of the 2 proton beam centres, and free accommodation is provided for patients and a carer at the proton beam centres. As with any radiotherapy there may be some long-term side effects. The study doctor or nurse will go through these with trial patients and this information is included in the patient information sheet. The adverse events from Proton beam therapy are considered to be low risk, as the concept of Proton beam therapy is to negate the effects of radiation to the healthy tissues surrounding the tumour, mainly healthy lung and heart tissue. The treating team will be monitoring patients for any side effects during and after treatment and will be taking care of any long-term adverse events for up to a year after surgery. There may be no direct benefit to research participants and this is explained in the patient information sheet. Research participants enrolled in the trial will have a 50% chance of receiving PBT for their oesophageal cancer, which is not currently available off trial, which may or may not improve their survival and quality of life from potentially fewer side effects than standard photon based radiotherapy. With 2 proton beam centres now in England, patients will no longer have to travel overseas for their PBT treatment. Patients in this study will have access to this new treatment, possibly increasing the chances of a long-term cure. Proton beam therapy may make immunotherapy easier to tolerate and possibly more effective. However, none of this is proven and there is no guarantee that individual patients will benefit directly from taking part in this study. We hope the information we gain from the study will benefit people who develop oesophageal cancer in the future. If the trial is a success and shows PBT treatment is better than photon beam radiotherapy then the standard of care may change in future.

Where is the study run from?

University College London (UK)

When is the study starting and how long is it expected to run for?

January 2024 to June 2032

Who is funding the study?
Cancer Research UK
The Taylor Family Foundation (UK)

Who is the main contact?
ctc.protieus@ucl.ac.uk

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-proton-beam-radiotherapy-for-oesophageal-cancer-and-gastroesophageal-junction>

Contact information

Type(s)
Scientific

Contact name
Dr Natasha Hava

Contact details
Cancer Research UK & UCL Cancer Trials Centre, 90 Tottenham Court Road
London
United Kingdom
W1T 4TJ
+44 207 679 9608
ctc.protieus@ucl.ac.uk

Type(s)
Principal investigator

Contact name
Prof Maria Hawkins

ORCID ID
<https://orcid.org/0000-0002-6669-0628>

Contact details
Department of Medical Physics & Biomedical Engineering Faculty of Engineering Science
University College London
London
United Kingdom
WC1E 6BT
+44 20 7679 0262 Ext: 30262
m.hawkins@ucl.ac.uk

Additional identifiers

Integrated Research Application System (IRAS)
329646

Central Portfolio Management System (CPMS)

Study information

Scientific Title

A randomised Phase II trial comparing proton versus photon-based neoadjuvant chemoradiation, followed by standard therapy, in oesophageal cancer

Acronym

PROTIEUS

Study objectives

Proton beam therapy given concurrently with chemotherapy before surgery significantly reduces the risk of severe toxicity and prevents delay of post-operative immunotherapy when compared with standard photon radiotherapy for oesophageal cancer.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 23/01/2024, The London - Camden & Kings Cross Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8086; CamdenandKingsCross.REC@hra.nhs.uk), ref: 23/LO/0964

Study design

Interventional randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Oesophageal cancer

Interventions

Current interventions as of 06/02/2026:

Eligible patients will be allocated by a computer devised programme into one of the treatment groups: A) a group receiving proton beam radiotherapy (PBT) or B) a group receiving standard of care treatment photon radiotherapy. All patients will receive 3 weeks of daily radiation and 5-7 courses of chemotherapy once weekly/fortnightly, with/without immunotherapy, followed by surgery. Patients in PBT group will travel to one of the proton beam centres either in Manchester or London. After chemoradiotherapy, all patients will have surgery and they will receive up to 4 fortnightly cycles of chemotherapy and/or immunotherapy for up to 1 year after their surgery, which starts approximately 4 to 12 weeks after surgery. The frequency when the patient should receive immunotherapy, for example, once every 2 or 4 weeks, will depend on the local hospital's policy.

After finishing surgery, all patients will be seen at clinic (follow-up visits) at the first month after the surgery, then every 3 months for up to a 1 year. Further follow-up data will be collected

remotely via a data collection service called NHS Digital (NHS England data registries). There is also a translational research component where extra blood will be taken from patients, and tissue samples from the diagnostic biopsy and surgical specimen will be collected for use in research.

Previous interventions:

Eligible patients will be allocated by a computer devised programme into one of the treatment groups: A) a group receiving proton beam radiotherapy (PBT) or B) a group receiving standard of care treatment photon radiotherapy. All patients will receive 3 weeks of daily radiation and 5 courses of chemotherapy once weekly, followed by surgery. Patients in PBT group will travel to one of the proton beam centres either in Manchester or London. After chemoradiotherapy, all patients will have surgery and if they have a small amount of remaining cancer cells (residual disease) after surgery, they will receive immunotherapy for up to 1 year after their surgery, approximately 4 to 12 weeks after surgery. The frequency when the patient should receive immunotherapy, for example, once every 2 or 4 weeks, will depend on the local hospital's policy.

After finishing surgery, all patients will be seen at clinic (follow-up visits) at the first month after the surgery, then every 3 months for up to a 1 year. Further follow-up data will be collected remotely via a data collection service called NHS Digital (NHS England data registries).

There is also a translational research component where extra blood and tissue samples will be taken from patients.

Intervention Type

Procedure/Surgery

Primary outcome(s)

Frequency and percentage of patients that experience severe post operative complications prior to or at the follow-up assessment 3 months after surgery measured using adverse event data entered on the database by sites which is graded using both the CTCAE and the Clavien Dindo Scale

Key secondary outcome(s)

Preliminary data on longer term efficacy outcomes following 1 year of adjuvant immunotherapy for patients that do not achieve pathologic complete response at surgery measured using survival data and the number and percentages of different types of disease recurrences

Completion date

01/06/2032

Eligibility

Key inclusion criteria

1. 16 years of age or older
2. Histologically confirmed diagnosis of oesophageal adenocarcinoma (OAC) or squamous cell carcinoma (OSCC)
3. Tumour of the thoracic oesophagus or gastroesophageal junction with distal maximum extension no more than 3 cm beyond the gastroesophageal junction
4. cT stage ≥ 2 and/or cN stage $\geq 0-2$ defined by AJCC 8th edition
5. ECOG performance status 0-1
6. Suitable for and fit to receive curative neoadjuvant Chemoradiotherapy followed by surgery by an Upper GI MDT

7. Suitable for and fit to receive adjuvant Immunotherapy according to local guidelines
8. Adequate cardiovascular and respiratory function for surgery in the opinion of the surgical team within 4 weeks prior to randomisation
9. Willing and able to give written informed consent and able to comply with treatment and follow up schedule
10. Willing and able to undergo treatment at a PBT centre (i.e. UCLH or The Christie) if randomised to Proton Arm

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

16 years

Upper age limit

100 years

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Metastatic disease or extensive nodal disease (N3).
2. Patients who have had previous treatment for invasive oesophageal carcinoma or gastro-oesophageal junction carcinoma (including Photo Dynamic Therapy or laser therapy for high grade dysplasia/carcinoma in-situ).
3. Patients with > 3cm mucosal extension of tumour into the stomach beyond the GOJ or where the superior extent is in the cervical oesophagus
4. Tumour length based on position:
 - 4.1. Length of primary tumour >10 cm in thorax, or
 - 4.2. >12 cm in the gastroesophageal junction or lower third of the oesophagus, or
 - 4.3. Total length of disease (primary tumour and involved lymph nodes) length >14 cm for lower third tumours.
5. Patients with unstable angina, uncontrolled hypertension, cardiac failure or arrhythmia and other clinically significant cardiac disease.
6. Patients with an oesophageal stent (patients requiring a PEG/RIG/feeding jejunostomy for nutritional purposes ARE eligible).
7. No relevant co-morbidities, including Usual Interstitial Pneumonia (UIP) pulmonary fibrosis and connective tissue disorders.
8. History of other malignancy likely to interfere with the protocol treatment (e.g. patients with previously treated malignancy who have been disease-free for < 1 year, or patients with active malignancy undergoing treatment). Exceptions:
 - 8.1. Subjects who have been successfully treated and disease-free for > 3 years,

- 8.2. A history of treated non-melanoma skin cancer,
- 8.3. Successfully treated in situ carcinoma,
- 8.4. CLL in stable remission, or indolent prostate cancer requiring no or only anti-hormonal therapy.
- 9. Any other situation, which in the opinion of the local PI, makes the patient unsuitable for this trial.
- 10. Women who are pregnant or breastfeeding.
- 11. Patients unable to adhere to the contraception guidance in the protocol.

Date of first enrolment

11/06/2024

Date of final enrolment

01/02/2028

Locations

Countries of recruitment

United Kingdom

England

Wales

Study participating centre

University College London Hospitals NHS Foundation Trust

250 Euston Road

London

England

NW1 2PG

Study participating centre

The Clatterbridge Cancer Centre NHS Foundation Trust

Clatterbridge Hospital

Clatterbridge Road

Bebington

Wirral

England

CH63 4JY

Study participating centre

Guys and St Thomas' NHS Foundation Trust

249 Westminster Bridge Road

London
England
SE1 7EH

Study participating centre

Norfolk and Norwich University Hospitals NHS Foundation Trust

Colney Lane
Colney
Norwich
England
NR4 7UY

Study participating centre

Royal Free London NHS Foundation Trust

Royal Free Hospital
Pond Street
London
England
NW3 2QG

Study participating centre

Swansea Bay University Local Health Board

Tonna Hospital
Tonna Uchaf
Tonna
Neath
Wales
SA11 3LX

Study participating centre

Leeds Teaching Hospitals NHS Trust

St. James's University Hospital
Beckett Street
Leeds
England
LS9 7TF

Study participating centre

The Christie NHS Foundation Trust

550 Wilmslow Road
Withington

Manchester
England
M20 4BX

Study participating centre

Hull University Teaching Hospitals NHS Trust

Hull Royal Infirmary
Anlaby Road
Hull
England
HU3 2JZ

Study participating centre

Royal Devon University Healthcare NHS Foundation Trust

Royal Devon University NHS Ft
Barrack Road
Exeter
England
EX2 5DW

Study participating centre

Cambridge University Hospitals NHS Foundation Trust

Cambridge Biomedical Campus
Hills Road
Cambridge
England
CB2 0QQ

Study participating centre

Oxford University Hospitals NHS Foundation Trust

John Radcliffe Hospital
Headley Way
Headington
Oxford
England
OX3 9DU

Study participating centre

University Hospitals Plymouth NHS Trust

Derriford Hospital
Derriford Road

Derriford
Plymouth
England
PL6 8DH

Study participating centre

Velindre NHS Trust

Unit 2
Charnwood Court
Heol Billingsley
Cardiff
Wales
CF15 7QZ

Sponsor information

Organisation

University College London

ROR

<https://ror.org/02jx3x895>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Funder Name

The Taylor Family Foundation

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	version 3.0	08/01/2026	06/02/2026	No	Yes
Participant information sheet	version 3.0	08/01/2026	06/02/2026	No	Yes
Protocol file	version 5.0		06/02/2026	No	No